Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells

Oncogene

Volumn 33, Issue 29, 2014, Pages 3869-3877

  Chen, Z ^a   Chen, J ^b   Gu, Y ^a   Hu, C ^a   Li, J L ^c   Lin, S ^a   Shen, H ^d   Cao, C ^a   Gao, R ^a   Li, J ^e   Ha, P K ^f   Kaye, F J ^a   Griffin, J D ^b   Wu, L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BURNHAM INSTITUTE   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

^e FUJIAN MEDICAL UNIVERSITY   (China)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AREG; CRTC1 MAML2; EGFR; mucoepidermoid carcinoma; salivary gland tumors

Indexed keywords

AMPHIREGULIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN;

ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, MUCOEPIDERMOID; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 19; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HETEROGRAFTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC;

EID: 84904598609     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.348     Document Type: Article

References (34)

1. Eveson JW. Salivary tumours. Periodontol 2000 2011; 57: 150-159
2. Bell D, Hanna EY. Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep 2012; 14: 166-174
3. Stenman G. Fusion oncogenes and tumor type specificity-insights from salivary gland tumors. Semin Cancer Biol 2005; 15: 224-235
4. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009; 106: 18740-18744
5. ONeill ID. New insights into the nature of Warthins tumour. J Oral Pathol Med 2009; 38: 145-149
6. ONeill ID. t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma. Oral Oncol 2009; 45: 2-9
7. Behboudi A, Enlund F, Winnes M, Andren Y, Nordkvist A, Leivo I.et al.. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 2006; 45: 470-481
8. Enlund F, Behboudi A, Andren Y, Oberg C, Lendahl U, Mark J.et al.. Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthins tumors. Exp Cell Res 2004; 292: 21-28
9. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T.et al.. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003; 33: 208-213
10. Kumar V, Abbas A, Fausto N. Robbins &Cotran Pathologic Basis of Disease. 7th edn (Elsevier, Saunders, 2005).
11. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol 2010; 34: 1106-1121
12. Chiosea SI, Dacic S, Nikiforova MN, Seethala RR. Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: clinical implications. Laryngoscope 2012; 122: 1690-1694
13. Fehr A, Roser K, Belge G, Loning T, Bullerdiek J. A closer look at Warthin tumors and the t(11;19). Cancer Genet Cytogenet 2008; 180: 135-139
14. Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H.et al.. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J 2005; 24: 2391-2402
15. Iourgenko V, Zhang W, Mickanin C, Daly I, Jiang C, Hexham JM.et al.. Identification of a family of cAMP response element-binding protein coactivators by genomescale functional analysis in mammalian cells. Proc Natl Acad Sci USA 2003; 100: 12147-12152
16. Conkright MD, Canettieri G, Screaton R, Guzman E, Miraglia L, Hogenesch JB.et al.. TORCs: transducers of regulated CREB activity. Mol Cell 2003; 12: 413-423
17. Komiya T, Coxon A, Park Y, Chen WD, Zajac-Kaye M, Meltzer P.et al.. Enhanced activity of the CREB co-Activator Crtc1 in LKB1 null lung cancer. Oncogene 2010; 29: 1672-1680
18. Altarejos JY, Montminy M. CREB and the CRTC co-Activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 2011; 12: 141-151
19. Gu Y, Lin S, Li JL, Nakagawa H, Chen Z, Jin B.et al.. Altered LKB1/CREB-regulated transcription co-Activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012; 31: 469-479
20. Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002; 22: 7688-7700
21. McElhinny AS, Li JL, Wu L. Mastermind-like transcriptional co-Activators: emerging roles in regulating cross talk among multiple signaling pathways. Oncogene 2008; 27: 5138-5147
22. Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA.et al.. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res 2005; 65: 7137-7144
23. Komiya T, Park Y, Modi S, Coxon AB, Oh H, Kaye FJ. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene 2006; 25: 6128-6132
24. Canettieri G, Coni S, Della Guardia M, Nocerino V, Antonucci L, Di Magno L.et al.. The coactivator CRTC1 promotes cell proliferation and transformation via AP-1. Proc Natl Acad Sci USA 2009; 106: 1445-1450
25. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 2011; 1816: 119-131
26. Grisanti S, Amoroso V, Buglione M, Rosati A, Gatta R, Pizzocaro C.et al.. Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. J Med Case Reports 2008; 2: 320
27. Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW.et al.. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer 2008; 61: 30-34
28. ONeill ID. Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene. Lung Cancer 2009; 64: 129-130
29. Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A.et al.. Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 2010; 103: 510-516
30. Anzick SL, Chen WD, Park Y, Meltzer P, Bell D, El-Naggar AK.et al.. Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosomes Cancer 2010; 49: 59-69
31. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F.et al.. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14: 6963-6973
32. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W.et al.. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11: 795-805
33. Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR.et al.. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007; 13: 1540-1551
34. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-Activator for NOTCH receptors. Nat Genet 2000; 26: 484-489.